Mexico - Delayed Quote MXN

Ocugen, Inc. (OCGN.MX)

Compare
13.35
0.00
(0.00%)
At close: February 25 at 1:19:14 PM CST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for OCGN.MX

Recent News: OCGN.MX

View More

Ocugen's Gene Therapies Receive EMA Advanced Therapy Classification for Vision Loss Treatment
PREMIUM
MT Newswires 4 hours ago
Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease
GlobeNewswire 7 hours ago
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease
GlobeNewswire 4 days ago
Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire 10 days ago
Why Ocugen (OCGN) Is Advancing Today

Why Ocugen (OCGN) Is Advancing Today
Insider Monkey 17 days ago
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
GlobeNewswire 19 days ago
Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa
GlobeNewswire 28 days ago
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19
GlobeNewswire last month
Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment

Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment
Clinical Trials Arena last month
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
GlobeNewswire last month
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
GlobeNewswire last month
View More

Related Tickers

INO.MX Inovio Pharmaceuticals, Inc.
40.00
0.00%
 
ATOS.MX Atossa Therapeutics, Inc.
14.70
-8.13%
 
NRSNW NeuroSense Therapeutics Ltd.
0.2147
+7.35%
 
MRNA.MX Moderna, Inc.
624.80
+0.29%
 
ENTO Entero Therapeutics, Inc.
0.6100
+23.31%
 
NRSN NeuroSense Therapeutics Ltd.
1.0500
-4.11%
 
ITRM Iterum Therapeutics plc
1.3300
-4.66%
 
ATOS Atossa Therapeutics, Inc.
0.7410
-3.23%
 
SLS SELLAS Life Sciences Group, Inc.
1.1600
-1.69%
 
INO Inovio Pharmaceuticals, Inc.
1.8400
-7.07%